Pharmacotherapy of inflammatory bowel disease

References

• Thayer WR Jr. Inflammatory bowel disease: where are the frontiers? Med Clin North Am 1980: 64(6): 1221–31
   PubMed Web of Science ®Google Scholar
• Svartz N. Salazopyrin. a new sulfanilamide preparation. A Therapeutic results in rheumatic polyarthritis. B. Therapeutic results in ulcerative colitis. C. Toxic manifestations in treatment with sulfanilamide preparations. Acta Med Scand 1942: 110(6): 577–98
   Google Scholar
• Baron JH, Connell AM, Lennard-Jones JE, et al. Sulphasalazine and salicylazosulphaclimidine in ulcerative colitis. Lancet 1962: 1(May 26): 1094–6
   PubMed Web of Science ®Google Scholar
• Dick AP, Grayson MJ, Carpenter RG, et al. Controlled trial of sulphasalazine in the treatment of ulcerative colitis. Gut 1964: 5(Oct): 437–42
   PubMed Web of Science ®Google Scholar
• Misiewicz JJ, Lennard-Jones JE, Connell AM, et al. Controlled trial of sulphasalazine in maintenance therapy for ulcerative colitis. Lancet 1965: 1(Jan 23): 185–8
   Web of Science ®Google Scholar
• Dissanayake AS, Truelove SC. A controlled therapeutic trial of long-term maintenance treatment of ulcerative colitis with sulphazalazine (Salazopyrin). Gut 1973: 14(Dec): 923–6
   PubMed Web of Science ®Google Scholar
• Anthonisen P. Barany F, Folkenborg O, et al. The clinical effect of salazo-sulphapyridine (Salazopyrin) in Crohn's disease: a controlled double-blind study. Scand J Gastroenterol 1974: 9(6): 549–54
   PubMed Web of Science ®Google Scholar
• Summers RW, Switz DM, Sessions JT, et al. National Cooperative Crohn's Disease Study: results of drug treatment. Gastroenterology 1979: 77(4 Pt 2): 847–69
   PubMed Web of Science ®Google Scholar
• Dixon JS. Biochemical and clinical changes in rheumatoid arthritis: their relation to the action of antirheumatoid drugs. Semin Arthritis Rheum 1982: 12(2): 191–207
   PubMed Web of Science ®Google Scholar
• Bird HA, Dixon JS, Pickup MB, et al. A biochemical assessment of sulphasalazine in rheumatoid arthritis. J Rheumatol 1982: 9(Jan-Feb): 36–45
   PubMed Web of Science ®Google Scholar
• Das KM, Eastwood MA, McManus JP, et al. The role of the colon in the metabolism of salicylazosulphapyridine. Scand J Gastroenterol 1974: 9(2): 137–41
   PubMed Web of Science ®Google Scholar
• Das KM, Eastwood MA, McManus JP, et al. The metabolism of salicylazosulphapyridine in ulcerative colitis. 1. The relationship between metabolites and the response to treatment in inpatients. Gut 1973: 14(Aug): 631–6
   PubMed Web of Science ®Google Scholar
• Das KM. The management of Crohn's disease, In: Weterman I. Pena S. Booth CC. eds. Proceedings of the workshop on Crohn's disease. Leyden 1975. New York: Elsevier North Holland (Excerpta Medical. 1976: 161–71
   Google Scholar
• Das KM, Chowdhury JR, Zapp B, et al. Small bowel absorption of sulfasalazine and its hepatic metabolism in human beings, cats and rats. Gastroenterology 1979: 77(2): 280–4
   PubMed Web of Science ®Google Scholar
• Schroder H, Campbell DE. Absorption, metabolism, and excretion of salicylazosulfapyridine in man. Clin Pharmacol Ther 1972: 13(Jul-Aug): 539–51
   PubMed Web of Science ®Google Scholar
• Das KM, Sternlieb I. Salicylazosulfapyridine in inflammatory bowel disease. Am J Dig Dis 1975: 20(10): 971–6
   PubMedGoogle Scholar
• Walker R. The metabolism of azo compounds: a review of the literature. Food Cosmet Toxicol 1970: 8(Dec): 659–76
   PubMedGoogle Scholar
• Peppercorn MA. Goldman P. The role of intestinal bacteria in the metabolism of salicylazosulfapyridine. J Pharmacol Exp Ther 1972: 181(Jun): 555–62
   PubMed Web of Science ®Google Scholar
• Das KM. Eastwood MA. Acetylation polymorphism of sulfapyridine in patients with ulcerative colitis and Crohn's disease. Clin Pharmacol Ther 1975: 18(5Pt 1): 514–20
   PubMed Web of Science ®Google Scholar
• Das KM. Eastwood MA. McManus JP, et al. Adverse reactions during salicylazosulfapyridine therapy and the relation with drug metabolism and acetylator phenotype. N Engl J Med 1973: 289(Sep 6): 491–5
   PubMed Web of Science ®Google Scholar
• Goldman P, Peppercorn MA. Drug therapy: sulfasalazine N Engl J Med 1975: 293(1): 20–3
   PubMed Web of Science ®Google Scholar
• Cowan GO, Das KM, Eastwood MA. Further studies of sulphasalazine metabolism in the treatment of ulcerative colitis. Br Med J 1977: 2(Oct 22): 1057–9
   PubMed Web of Science ®Google Scholar
• Das KM, Eastwood MA, McManus JP, et al. The metabolism of salicylazo-sulphapyridine in ulcerative colitis. 2. The relationship between metabolites and the progress of the disease studied in out-patients. Gut 1973: 14(Aug): 637–41
   PubMedGoogle Scholar
• Azad Khan AK, Piris J, Truelove SC. An experiment to determine the active therapeutic moiety of sulphasalazine. Lancet 1977: 2(8044): 892–5
   PubMed Web of Science ®Google Scholar
• van Hees PA, Bakker JH, van Tongeren JH. Effect of sulphapyridine. 5-aminosalicylic acid, and placebo in patients with idiopathic proctitis: a study to determine the active therapeutic moiety of sulphasalazine. Gut 1980: 21(7): 632–5
   PubMed Web of Science ®Google Scholar
• Robert A. Antisecretory, antiulcer, cytoprotective and diarrheogenic properties of prostaglandins. Prostaglandin Thromboxane Res 1976: 2: 507–20
   PubMedGoogle Scholar
• Gould SR, Lennard-Jones JE. Production of prostaglandins in ulcerative colitis and their inhibition by sulphasalazine. (Abstr) Gut 1976: 171(10): 828
   Google Scholar
• Sharon P, Ligumsky M. Rachmilewitz D, et al. Role of prostaglandins in ulcerative colitis: enhanced production during active disease and inhibition by sulfasalazine. Gastroenterology 1978: 75(4): 638–40
   PubMed Web of Science ®Google Scholar
• Ligumsky M, Karmeli F, Sharon P. et al. Enhanced thromboxane A2 and prostacyclin production by cultured rectal mucosa in ulcerative colitis and its inhibition by steroids and sulfasalazine. Gastroenterology 1981: 81(3): 444–9
   PubMed Web of Science ®Google Scholar
• Harris DW. Swan CH. Increased synthesis of prostaglandins in ulcerative colitis. Lancet 1977: 2(8030): 196
   PubMed Web of Science ®Google Scholar
• Butt AA, Collier HO, Gardiner PJ. et al. Proceedings: effects on prostaglandin biosynthesis of drugs affecting gastrointestinal function. Gut 1974: 15 (Apr): 344
   PubMed Web of Science ®Google Scholar
• Moore PK, Hoult JR, Laurie A. Prostaglandins and mechanism of action (of sulphasalazine) in ulcerative colitis. Lancet 1978: 2(8080): 98–9
   PubMed Web of Science ®Google Scholar
• Harris J, Archampong EQ, Clark CG. The effect of salazopyrin on water and electrolyte transport in the human colon measured in vivo and in vitro. Gut 1972: 13(Oct): 855
   PubMed Web of Science ®Google Scholar
• West B. Lendrum R. Hill MJ, et al. Effects of sulphasalazine (Salazopyrin) of faecal flora in patients with inflammatory bowel disease. Gut 1974: 15(12): 960–5
   PubMed Web of Science ®Google Scholar
• Holm G, Perlmann P. The effect of antimetabolites on the cytotoxicity by human lymphocytes. In: Advances in transplantation. Copenhagen: Munksgaard. 1968: 155–61
   Google Scholar
• Rubinstein A, Das KM, Melamed J, et al. Comparative analysis of systemic immunological parameters in ulcerative colitis and idiopathic proctitis: effects of sulfasalazine in vivo and in vitro. Clin Exp Immunol 1978: 33(2): 217–24
   PubMed Web of Science ®Google Scholar
• Stenson WF, Lobos E. Sulfasalazine inhibits the synthesis of chemotactic lipids by neutrophils. J Clin Invest 1982: 69(2): 494–7
   PubMed Web of Science ®Google Scholar
• Moertel CG, Bargen JA. A critical analysis of the use of salicylazosulfapyridine in chronic ulcerative colitis. Ann Intern Med 1959: 51 (Nov): 879–89
   PubMed Web of Science ®Google Scholar
• Truelove SC, Watkinson G, Draper G. Comparison of corticosteroid and sulphasalazine therapy in ulcerative colitis. Br Med J 1962: 2(5321): 1708–11
   PubMed Web of Science ®Google Scholar
• Lennard-Jones JE, Longmore AJ, Newell AC, et al. An assessment of prednisone, salazopyrin and topical hydrocortisone hemisuccinate used as outpatient treatment for ulcerative colitis. Gut 1960: 1(Sep): 217–22
   PubMed Web of Science ®Google Scholar
• Riis P, Anthonisen P, Wulff HR, et al. The prophylactic effect of salazosulphapyridine in ulcerative colitis during long term treatment: a double-blind trial on patients asymptomatic for one year. Scand J Gastroenterol 1973: 8(1): 71–4
   PubMed Web of Science ®Google Scholar
• Azad Khan AK, Howes DT, Piris J, et al. Optimum dose of sulphasalazine for maintenance treatment in ulcerative colitis. Gut 1980: 21(3): 232–40
   PubMed Web of Science ®Google Scholar
• Bargen JA. Regional enteritis: an evaluation of the present day therapeutic management. Ann Intern Med 1957: 47(Nov): 875–9
   PubMed Web of Science ®Google Scholar
• Wenckert A, Kristensen M, Eklund AE, et al. The long-term prophylactic effect of salazosulphapyridine (Salazopyrin) in primarily resected patients with Crohn's disease. A controlled double-blind trial. Scand J Gastroenterol 1978: 13(2): 161–7
   PubMed Web of Science ®Google Scholar
• Singleton JW, Summers RW, Kern F Jr, et al. A trial of sulfasalazine as adjunctive therapy in Crohn's disease. Gastroenterology 1979: 77(4 Pt 2): 887–97
   PubMed Web of Science ®Google Scholar
• Taffet SL, Das KM. Sulfasalazine: adverse effects and desensitization. Dig Dis Sci 1983: 28(9): 833–42
   PubMed Web of Science ®Google Scholar
• Singleton JW, Law DH, Kelley ML Jr, et al. National Cooperative Crohn's Disease Study: adverse reactions to study drugs. Gastroenterology 1979: 77(4 Pt 2): 870–82
   PubMed Web of Science ®Google Scholar
• van Hees PA van Elferen LW, van Rossum JM, et al. Hemolysis during salicylazosulfapyridine therapy. Am J Gastroenterol 1978: 70(5): 501–5
   PubMed Web of Science ®Google Scholar
• Taffet SL, Das KM. Desensitlzation of patients with Inflammatory bowel disease to sulfasalazine. Am J Med 1982: 73(4): 520–4
   PubMed Web of Science ®Google Scholar
• Korelitz BI, Present DH, Rubin PH, et al. Desensitization to sulfasalazine in allergic patients with IBD: an important therapeutic modality. (Abstr) Gastroenterology 1982: 82(5): 1104
   Web of Science ®Google Scholar
• Holdsworth CD. Sulfasalazine desensitization. Br Med J (Clin Res) 1981: 282(6258): 110
   PubMed Web of Science ®Google Scholar
• Das KM, Eastwood MA. Effect of iron and calcium on salicylazosulphapyridine metabolism. Scott Med J 1973: 18(Mar): 45–50
   Google Scholar
• Franklin JL, Rosenberg MA. Impaired folic acid absorption in inflammatory bowel disease: effects of salicylazosulfapyridine (Azulfidine). Gastroenterology 1973: 64(Apr): 517 25
   PubMed Web of Science ®Google Scholar
• Campbell AC, Skinner JM, Maclennan IC, et al. Immunosuppression in the treatment of inflammatory bowel disease. II. The effects of azathioprine on lymphoid cell populations in a double blind trial in ulcerative colitis. Clin Exp Immunol 1976: 24(2): 249–58
   PubMed Web of Science ®Google Scholar
• Shafii A, Chowdhury JR, Das KM. Absorption, enterohepatic circulation, and excretion of 5-aminosalicylic acid in rats. Am J Gastroenterol 1982: 77(5): 297–9
   PubMed Web of Science ®Google Scholar
• Rasmussen SN, Bondesen S, Hvidberg EF, et al. 5 aminosalicylic acid in a slow-release preparation: bioavailability, plasma level, and excretion in humans. Gastroenterology 1982: 83(5): 1062–70
   PubMed Web of Science ®Google Scholar
• Dew MJ, Harries AD, Evans N, et al. Maintenance of remission in ulcerative colitis with 5-amino salicylic add in high doses by mouth. Br Med J (Clin Res) 1983: 287(6384): 23–4
   PubMed Web of Science ®Google Scholar
• Bartalsky A. Salicylazobenzoic acid in ulcerative colitis. (Letter) Lancet 1982: 1(8278): 960
   PubMed Web of Science ®Google Scholar
• Jewell DP, Truelove SC. Disodium azodisalicylate in ulcerative colitis. (Letter) Lancet 1981: 2(8256): 1168–9
   PubMed Web of Science ®Google Scholar